



## PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

**Xolair**

**Phone: 800-728-7947**

**Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>	
	<b>Supervising Physician:</b>	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

**Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.**

<p>Q1. What diagnosis is this drug being prescribed for?</p> <p><input type="checkbox"/> IgE-mediated allergic asthma</p> <p><input type="checkbox"/> Chronic idiopathic urticaria</p> <p><input type="checkbox"/> Other</p>
<p>Q2. Please provide ICD code(s) for diagnosis.</p>
<p>Q3. Has the diagnosis been confirmed by an allergist within the prior year?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q4. Is the patient following allergen and irritant avoidance?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable - not a contributing factor to asthma or urticaria</p>
<p>Q5. If the diagnosis is chronic idiopathic urticaria, does the patient continue to be symptomatic despite H1 antihistamine therapy?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>



## PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

**Xolair**

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b> <b>Supervising Physician:</b>
Q6. If the diagnosis is IgE-mediated allergic asthma, what is the patient's baseline IgE level?	
Q7. If the diagnosis is IgE-mediated allergic asthma, what is the expected dose of Xolair?	
Q8. Is Xolair used as adjunct and not replacing immunotherapy or other forms of treatment in this patient? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Is the patient demonstrably complying with full controller pharmacotherapy including combined inhaled corticosteroid and long-acting bronchodilator therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q10. Will the dose of Xolair first be reduced or discontinued when this patient becomes well-controlled? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q11. Please indicate how poor control is demonstrated in this patient (please choose one of the following): <input type="checkbox"/> One hospital admission in the prior six months <input type="checkbox"/> Two emergency room or urgent care visits in the prior six months <input type="checkbox"/> Two months of daily oral corticosteroid use without significant tapering <input type="checkbox"/> Other events which are felt to indicate poor control (if option this is chosen, please elaborate in the Additional Comment field) <input type="checkbox"/> None of the above	
Q12. Has patient had a pulmonary profile has demonstrated evidence of reversible airways obstruction within the prior year? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q13. Who is the ENTITY that will be submitting the CLAIM for the DRUG and seeking reimbursement? <input type="checkbox"/> Pharmacy <input type="checkbox"/> Individual prescriber <input type="checkbox"/> Provider or specialty group <input type="checkbox"/> Facility <input type="checkbox"/> Other (please specify)	
Q14. Provide name and NPI of the billing entity	



## PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

**Xolair**

**Phone: 800-728-7947**

**Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b> <b>Supervising Physician:</b>
Q15. Will the claim for the drug be submitted as a MEDICAL claim or PHARMACY claim (Note: If a pharmacy will be submitting a MEDICAL claim for drug reimbursement, answer MEDICAL)?	
<input type="checkbox"/> Medical	<input type="checkbox"/> Pharmacy
Q16. I have provided the most recent chart note, labs, and additional clinical information to support the information provided on this request form.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q17. Additional Comments	

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

☐ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document